CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Practice Management

 

Radiologists Should Worry About Medical Device Tax, Too

By Whitney L.J. Howell | January 10, 2013

On January 1, the long-debated and much-opposed medical device tax went into effect. To date, medical device manufacturers have clearly stated their opposition, but industry leaders portend practicing radiologists also have reason to be concerned.

Barely a week old, this measure levies a 2.3 percent tax on all medical devices. The law calls for manufacturers to pay for the tax added to the sale price of the device, but many worry the cost will not only trickle down to providers, but will also, ultimately, stymy the progression of patient care by hindering research and development efforts.

(MORE: Poll: Concerned About the Medical Device Tax?)

“As radiologists, most of us chose the specialty because it’s a field that incentivizes technological innovation that can make enormous differences in patient care,” said Geraldine McGinty, MD, chair of the American College of Radiology (ACR) Economics Commission. “Payment or health care policies that would, in any way, negatively impact innovation are things that make us feel uncomfortable.”

The device tax will inevitably impact practitioners’ bottom lines, she said. The actual dollar amount is yet unknown, but manufacturers will be forced to pass some of the tax increase on to their customers. The price hike will likely be an unwelcome addition to existing imaging reimbursement cuts and the difficulties radiologists already face with collecting payments from patients. Equipment purchasing decisions could become more complicated or could be postponed, she said.

In addition to individual monetary concerns, radiologists should also worry about what the medical device tax could mean for their ability to provide the most up-to-date patient care. According to the Medical Imaging and Technological Alliance (MITA), this initiative is a job-killer because it makes outsourcing jobs overseas more attractive. But research and development efforts will also be a casualty, said MITA Executive Director Gail Rodriguez.

According to a recent MITA survey, 29 percent of manufacturers anticipate slicing into their research and development budgets as a way to cover the anticipated $287 million associated with the device tax. This change could leave providers without new technological innovations for treating patients, MITA said.

“Radiologists are responsible for caring for patients — diagnosing and staging cancer and tracking the success of therapies,” she said. “So putting taxes on companies responsible for creating better imaging technology can create a burden.”

In fact, a recent Pacific Research Institute report estimates medical device manufacturers will eventually curb research and development investments by $2 billion each year.

Despite the flurry of conversation about the medical device tax among radiology vendors and some leaders, most providers in daily practice have yet to focus on this cost increase, ACR’s McGinty said. They are more likely to still be focused on the drop in imaging utilization and how to combat that downward trend. But, she said, they’ll soon need to take a close look at their balance sheets and determine how the tax will affect their practice.

“The tax has been implemented, and it adds to an already challenging time for radiologists,” she said. “We’re an industry that provides a number of good technology jobs. Carrots, instead of sticks, for us, would be nice.”
 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by David Freiman | January 17, 2013 1:29 PM EST

This tax affects us indirectly, too. A friend who works with a multinational device manufacturer headquarted in Europe described his last meeting with executive management. The tax is expected to cost their American division $2,000,000 the first year. All US R and D is being moved back to Europe. Whether manufacturing goes back to Europe depends on details in the tax that still have to be decided. The result is fewer American jobs and likely increased costs for the medical system. But I can also see that in my own INterventional filed that there will be less access to cutting edge technology and less participation by our IR physicians in it's R and D. This will further push use of new devices out of the US and leave us only long established devices and procedures. We will be even farther away from the forefront of IR.

Related Articles

Radiologists Should Worry About Medical Device Tax, Too

‘Fiscal Cliff’ Deal Includes Medical Imaging Cuts

How the Election Will Impact Radiologists

Poll: Concerned About the Medical Device Tax?






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
  • Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
  • Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
  • New AUA Guidelines for Prostate Cancer Screening
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Practice Management
Evidence on Practice Management
Guidelines on Practice Management
Patient Education on Practice Management
Clinical Trials on Practice Management
Practical Articles on Practice Management
Research and Reviews on Practice Management
All "Practice Management" results

CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy